

Agreement 9: Advanced Immunotherapy Access Program

Parties: ImmunoGenix Inc. and Singapore Ministry of Health Country: Singapore Disease Area: Non-Small Cell Lung Cancer Agreement Overview: This precision medicine agreement provides access to novel immunotherapy for advanced non-small cell lung cancer patients with specific genetic profiles. Targeting approximately 280 patients annually, this contract creates a structured payment approach that balances early access to innovative therapy with financial sustainability. The agreement incorporates comprehensive biomarker testing, response monitoring, and long-term surveillance.

Financial Structure:

- Pay-for-performance model: SGD 120,000 per patient for complete treatment course
- Payment schedule: 40% upfront (SGD 48,000), 60% (SGD 72,000) based on outcomes
- Response criteria:
 - 25% of outcome payment for objective response at 3 months by RECIST 1.1 criteria
 - 35% for progression-free survival at 6 months (exceeding median by 50%)
 - 40% for overall survival at 12 months (exceeding standard of care by 3+ months)
- Non-responder clause: Full refund if disease progression within 8 weeks of treatment initiation
- Annual effectiveness evaluation with price adjustment mechanism ($\pm 10\%$ based on real-world performance)
- Patient subsidy program with sliding scale based on household income (maximum 75% subsidy)
- Fast-track approval process: Conditional reimbursement with real-world evidence generation
- Combination therapy provision: Additional SGD 35,000 if standard chemotherapy must be added

Duration: 2 years with renewal options and performance review Special Provisions:

- Includes comprehensive companion diagnostic testing for PD-L1 expression, tumor mutational burden, and microsatellite instability
- Biomarker monitoring throughout treatment course
- Patient selection committee for borderline cases
- Immune-related adverse event management protocol
- Data collection for Asian-specific response patterns
- Integration with Singapore's National Electronic Health Record
- Patient support program including psychosocial services
- Treatment optimization research component with academic collaboration
- Genomic repository creation for future precision medicine applications

